

# Tirzepatide noninferior, superior to semaglutide for T2DM

June 29 2021

---



(HealthDay)—The dual glucose-dependent insulinotropic polypeptide

and glucagon-like peptide-1 receptor agonist, tirzepatide, is noninferior and superior to semaglutide for reducing glycated hemoglobin levels among patients with type 2 diabetes, according to a study published online June 25 in the *New England Journal of Medicine* to coincide with the annual meeting of the American Diabetes Association, held virtually from June 25 to 29.

Juan P. Frías, M.D., from the National Research Institute in Los Angeles, and colleagues randomly assigned 1,879 patients to receive tirzepatide 5 mg, 10 mg, or 15 mg, or semaglutide 1 mg in an open-label, 40-week, phase 3 trial. The mean glycated hemoglobin level was 8.28 percent at baseline and mean weight was 93.7 kg.

The researchers found that the estimated mean change from baseline in the glycated [hemoglobin levels](#) was  $-2.01$ ,  $-2.24$ ,  $-2.30$ , and  $-1.86$  percent with tirzepatide 5 mg, 10 mg, or 15 mg, and semaglutide, respectively; the estimated differences were  $-0.15$ ,  $-0.39$ , and  $-0.45$  percent between the 5-, 10-, and 15-mg tirzepatide groups, respectively, and the semaglutide group. All doses of tirzepatide were noninferior and superior to semaglutide. Greater reductions in [body weight](#) were seen with tirzepatide than semaglutide (least-squares mean estimated treatment difference,  $-1.9$ ,  $-3.6$ , and  $-5.5$  kg, respectively).

"Given the driving force of obesity in the epidemic of diabetes, as well as in the risks of cardiovascular and [chronic kidney disease](#), this observation may lead to consideration of the use of tirzepatide for [weight loss](#)," writes the author of an accompanying editorial.

Several authors of the study and the author of the editorial disclosed financial ties to [pharmaceutical companies](#), including Eli Lilly, which manufactures tirzepatide and funded the study.

**More information:** [Abstract/Full Text](#)

[Editorial](#)

[More Information](#)

Copyright © 2021 [HealthDay](#). All rights reserved.

Citation: Tirzepatide noninferior, superior to semaglutide for T2DM (2021, June 29) retrieved 27 April 2024 from

<https://medicalxpress.com/news/2021-06-tirzepatide-noninferior-superior-semaglutide-t2dm.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.